SCHEMBL6142299

SCHEMBL6142299

CNC1CCC(N(C)C)CC1

nearest known ligand 0.34

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
IRAK4 Q9NWZ3 19/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8214008 1.00 IRAK4 (0.34) IRAK4
SCHEMBL14724552 1.00 IRAK4 (0.34) IRAK4
SCHEMBL10109671 0.93 IRAK4 (0.32) IRAK4
SCHEMBL19723229 0.84
SCHEMBL17488360 0.84
SCHEMBL17488359 0.84
SCHEMBL530404 0.78 KDM1A (0.38)
SCHEMBL665282 0.78 KDM1A (0.38)
SCHEMBL17458 0.78
SCHEMBL11525280 0.78 KDM1A (0.38)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250161906-A1 METHOD FOR REMOVING GASES EVONIK OPERATIONS GMBH (DE) 2025-05-22 US disclosed
EP-4556101-A1 GAS REMOVAL METHOD Evonik Operations GmbH (DE) 2025-05-21 EP disclosed
US-20250034165-A1 COMPOUND CONTAINING CYCLOALKYL OR HALOALKYL CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) 2025-01-30 US disclosed
EP-4442690-A1 COMPOUND CONTAINING CYCLOALKYL OR HALOALKYL Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) 2024-10-09 EP disclosed
EP-3640248-B1 AMINOPYRIMIDINE DERIVATIVES, PREPARATION METHOD THEREFOR AND USE THEREOF BEIJING ADAMADLE BIOTECHNOLOGY LLC (CN) 2023-08-23 EP disclosed
WO-2023098730-A1 COMPOUND CONTAINING CYCLOALKYL OR HALOALKYL 正大天晴药业集团股份有限公司 2023-06-08 WO disclosed
WO-2023016434-A1 COMPOUNDS TARGETING MUTANT OF P53 JACOBIO PHARMACEUTICALS CO., LTD. (CN) 2023-02-16 WO disclosed
US-11352352-B2 Aminopyrimidine compound, preparation method therefor and use thereof Beijing Adamadle Biotechnology Limited Liability Company (CN) 2022-06-07 US disclosed
US-11180474-B2 Dimethoxyphenyl substituted indole compounds as TLR7, TLR8 or TLR9 inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2021-11-23 US disclosed
EP-3490983-B1 DIMETHOXYPHENYL SUBSTITUTED INDOLE COMPOUNDS AS TLR7, TLR8 OR TLR9 INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2021-02-17 EP disclosed
US-7626021-B2 Fused ring heterocycle kinase modulators SGX PHARMACEUTICALS, INC. (US) 2009-12-01 US disclosed
US-7626021-B2 Fused ring heterocycle kinase modulators SGX PHARMACEUTICALS, INC. (US) 2009-12-01 US disclosed
US-20070287711-A1 FUSED RING HETEROCYCLE KINASE MODULATORS SGX PHARMACEUTICALS, INC. (US) 2007-12-13 US disclosed
US-20070287711-A1 FUSED RING HETEROCYCLE KINASE MODULATORS SGX PHARMACEUTICALS, INC. (US) 2007-12-13 US disclosed
EP-1016694-B1 Pigment dispersants, pigment dispersions and writing or recording pigment inks DAINICHISEIKA COLOR CHEM (JP) 2005-01-12 EP disclosed
EP-1024179-B1 Pigment dispersions for color filters, fabrication process of color filters, and color filters DAINICHISEIKA COLOR & AMP CHEM (JP) 2003-12-17 EP disclosed
US-6302953-B1 TRIAZINE-SUBSTITUTED ANTHRAQUINONE DISPERSANTS DAINICHISEIKA COLOR CHEMICALS MFG. CO., LTD. (JP) 2001-10-16 US disclosed
US-6299676-B1 DISPERSANT FOR ORGANIC PIGMENTS, FORMING PIGMENT DISPERSIONS HAVING EXCELLENT FLUIDITY, DISPERSION STABILITY, STORAGE STABILITY DAINICHISEIKA COLOR & CHEMICALS MFG. CO., LTD. (JP) 2001-10-09 US disclosed
EP-1024179-A1 Pigment dispersions for color filters, fabrication process of color filters, and color filters DAINICHISEIKA COLOR & CHEMICALS MFG. CO. LTD. (JP) 2000-08-02 EP disclosed
EP-1016694-A2 Pigment dispersants, pigment dispersions and writing or recording pigment inks DAINICHISEIKA COLOR & CHEMICALS MFG. CO. LTD. (JP) 2000-07-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070287711-A1 FUSED RING HETEROCYCLE KINASE MODULATORS MAP3K20, TTK, MAP3K19 IRAK4 424/4885
US-11180474-B2 Dimethoxyphenyl substituted indole compounds as TLR7, TLR8 or TLR9 inhibitors TLR9, TLR7, TLR8 IRAK4 15/4885
US-11352352-B2 Aminopyrimidine compound, preparation method therefor and use thereof WEE1, WEE2, EGFR IRAK4 952/4885
US-20250034165-A1 COMPOUND CONTAINING CYCLOALKYL OR HALOALKYL KRAS, HRAS, VHL IRAK4 4837/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.